Receptor News and Research

RSS

Algal metabolites as novel drugs against viruses

A new review article published in the Journal of Biotechnology has provided information on various nutraceutical metabolites extracted from algae.

29 Mar 2022

Is SARS-CoV-2 a Superantigen?

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), scientists have been conducting extensive studies to understand various aspects of the virus. Researchers have stated that SARS-CoV-2 manifests several biological and clinical consequences of a superantigen

29 Mar 2022

Northwestern scientists continue to advance the understanding of COVID-19

As the COVID-19 pandemic enters its third year, Northwestern Medicine scientists continue to help advance the understanding of the disease and its impact, from investigating antibody protection against COVID-19 reinfection to elevating women in academic research and highlighting racial and ethnic disparities in COVID-19 hospital mortality in Illinois.

28 Mar 2022

Evaluating severity of influenza infection in ferrets with COVID-19 history

In a new study, researchers investigated the effect of SARS-CoV-2 exposure on the severity of influenza in ferrets.

28 Mar 2022

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

A recent study investigated the potency and functionality of T-cell and humoral responses against the SARS-CoV-2 wild-type strain and its variants.

28 Mar 2022

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Researchers evaluated the ability of RBD antibodies to bind to and neutralize SARS-CoV-2 Omicron variant.

28 Mar 2022

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

A new research paper published as an early release manuscript in the Nature Medicine journal compares the sensitivity of this strain as well as the earlier Delta and the newer BA.2 to therapeutic mAbs.

27 Mar 2022

SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

Researchers study the impact of pasteurization on specific Ig concentration against SARS-CoV-2 in milk from mRNA vaccinated lactating women.

27 Mar 2022

Study evaluates efficacy of sarilumab in severe/critical COVID-19 patients

Researchers discuss the results of a clinical trial to assess the efficacy and safety of IV sarilumab for the treatment of hospitalized COVID-19 patients.

27 Mar 2022

New method for generating binding proteins solves a long-standing challenge in drug development

A team of scientists has created a powerful new method for generating protein drugs. Using computers, they designed molecules that can target important proteins in the body, such as the insulin receptor, as well as vulnerable proteins on the surface of viruses.

25 Mar 2022

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

Researchers investigated the impact of mutations in the SARS-CoV-2 variants of interest and variants of concern on the properties of the cluster of differentiation 8 T lymphocytes.

25 Mar 2022

Researchers show how an important inhibitor binds to the A2A receptor

The A2A receptor regulates how vigorously the innate immune system attacks diseased cells.

25 Mar 2022

Study finds methylene blue is a low-micromolar inhibitor of the the SARS-CoV-2 spike protein and ACE2 interaction

A new study has focussed on screening and identification of possible SMIs of this PPI for COVID-19.

25 Mar 2022

Study explores macrophage susceptibility to SARS-CoV-2 virions

A new study investigated the susceptibility of macrophages to SARS-CoV-2 virions.

25 Mar 2022

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Researchers evaluated the neutralizing antibody titers and anti-receptor-binding domain immunoglobulin G titers in sera of kidney transplant recipients who were vaccinated against COVID-19 and treated with 300 mg dosage of Evusheld™

25 Mar 2022

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

Researchers used a CNN regression model to investigate the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex.

25 Mar 2022

Adaptive immunity against SARS-CoV-2 is persistent and robust in COVID-convalescent children

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection incites adaptive cellular immune responses. In many SARS-CoV-2 studies, peripheral blood is analyzed to study the immune responses. Now, a new study under consideration at the Nature Portfolio Journal analyzes the peripheral blood, tonsils, and adenoids of children to understand local and systemic immune responses to SARS-CoV-2.

25 Mar 2022

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

A team of international scientists has developed an mRNA-based coronavirus disease 2019 (COVID-19) vaccine encoding the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant. The vaccine candidate has shown high efficacy in inducing neutralizing antibodies and protecting against delta infection in mice. The study is currently available on the bioRxiv* preprint server.

24 Mar 2022

IgG Fc glycosylation: A marker for severe COVID-19

Researchers suggest that low anti-spike IgG1 glycosylation, sialyation, and high bisection are markers of severe COVID-19.

24 Mar 2022

Receptor News and Research

Algal metabolites as novel drugs against viruses

Is SARS-CoV-2 a Superantigen?

Northwestern scientists continue to advance the understanding of COVID-19

Evaluating severity of influenza infection in ferrets with COVID-19 history

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

Study evaluates efficacy of sarilumab in severe/critical COVID-19 patients

New method for generating binding proteins solves a long-standing challenge in drug development

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

Researchers show how an important inhibitor binds to the A2A receptor

Study finds methylene blue is a low-micromolar inhibitor of the the SARS-CoV-2 spike protein and ACE2 interaction

Study explores macrophage susceptibility to SARS-CoV-2 virions

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

Adaptive immunity against SARS-CoV-2 is persistent and robust in COVID-convalescent children

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

IgG Fc glycosylation: A marker for severe COVID-19

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News